Search form
Search
contact us
Navigation
home
boards
job center
job ratings
cp wire
device news
pharmagather
catering
advertise
Legal Help
login/register
You are here
Home
»
companies
» hemophilia
hemophilia
Sanofi revises fitusiran dosing to cut risk of thrombotic events in hemophilia phase 3
Sanofi revises fitusiran dosing to cut risk of thrombotic events in hemophilia phase 3
Fierce Biotech
Sanofi
fitusiran
hemophilia
hemophilia A
hemophila B
Flag link:
Gene therapy for hemophilia: So close, yet so far away
Gene therapy for hemophilia: So close, yet so far away
BioPharma Dive
hemophilia
hemophilia A
hemophilia B
gene therapy
Biomarin
uniQure
Flag link:
Novo invests in Hemab, a company going against the hemophilia gene therapy grain with a plan for bispecifics
Novo invests in Hemab, a company going against the hemophilia gene therapy grain with a plan for bispecifics
Endpoints
Novo Nordisk
Novo Holdings
Hemab
hemophilia
Flag link:
Sanofi accepts a lengthy delay as its hemophilia drug fitusiran resumes a PhIII after safety fears forced a halt
Sanofi accepts a lengthy delay as its hemophilia drug fitusiran resumes a PhIII after safety fears forced a halt
Endpoints
Sanofi
fitusiran
FDA
hemophilia
Flag link:
Pfizer doses first participant in phase 3 study evaluating anti-TFPI investigational therapy
Pfizer doses first participant in phase 3 study evaluating anti-TFPI investigational therapy
Pharmaceutical Business Review
Pfizer
clinical trials
marstacimab
hemophilia
anti-TFPI
Flag link:
Sanofi/Alnylam’s haemophilia drug hits another safety speed-bump
Sanofi/Alnylam’s haemophilia drug hits another safety speed-bump
Pharmaforum
hemophilia
Sanofi
Roche
fitusiran
Flag link:
Sharp knives and hemophilia? No problem in Roche's new work-life miniseries
Sharp knives and hemophilia? No problem in Roche's new work-life miniseries
Fierce Pharma
hemophilia
Roche
pharma marketing
Flag link:
Sanofi's hemophilia drug comes into focus as delays hit a key competitor
Sanofi's hemophilia drug comes into focus as delays hit a key competitor
BioPharma Dive
Sanofi
hemophilia
hemophilia A
BIVV001
Flag link:
Novo gets PhIII hemophilia trials for a Roche rival back on track after completing work-around on blood clot threat
Novo gets PhIII hemophilia trials for a Roche rival back on track after completing work-around on blood clot threat
Endpoints
Novo Nordisk
hemophilia
concizumab
clinical trials
Flag link:
Sangamo R&D chief hits the exit as it splits R&D into separate units
Sangamo R&D chief hits the exit as it splits R&D into separate units
Fierce Biotech
Sangamo
R&D
Pfizer
hemophilia
Flag link:
Sigilon picks up $80M to test hemophilia cell therapy in humans
Sigilon picks up $80M to test hemophilia cell therapy in humans
Fierce Biotech
Siglion Therapeutics
cell terhapy
hemophilia
Flag link:
Novo Nordisk Pauses 3 Clinical Trials Testing Hemophilia Therapy
Novo Nordisk Pauses 3 Clinical Trials Testing Hemophilia Therapy
Xconomy
Novo Nordisk
clinical trials
concizumab
hemophilia
Flag link:
BioMarin Considers $3 Million Price Tag for New Hemophilia Gene Therapy
BioMarin Considers $3 Million Price Tag for New Hemophilia Gene Therapy
Motley Fool
Biomarin
JPMHC 2020
drug pricing
valrox
hemophilia
Flag link:
BioMarin sets gene therapy sights beyond hemophilia
BioMarin sets gene therapy sights beyond hemophilia
BioPharma Dive
Biomarin
hemophilia
gene therapy
Flag link:
Value-based pricing for gene therapy? Maybe not ready for hemophilia
Value-based pricing for gene therapy? Maybe not ready for hemophilia
Biopharma Dive
Biomarin
hemophilia
hemophilia A
gene therapy
valoctocogene roxaparvovec
uniQure
hemophilia B
etranadez
Flag link:
Sangamo keeps pressure on rivals with updated hemophilia data
Sangamo keeps pressure on rivals with updated hemophilia data
Biopharma Dive
ASH2019
Pfizer
Sangamo
hemophilia
SB-525
Flag link:
Why Novo Nordisk should buy Uniqure
Why Novo Nordisk should buy Uniqure
EP Vantage
Novo Nordisk
gene editing
hemophilia
uniQure
Bluebird Bio
Flag link:
The return of Vioxx: Can a drug once deemed deadly be relaunched to treat rare disease?
The return of Vioxx: Can a drug once deemed deadly be relaunched to treat rare disease?
Stat
Vioxx
hemophilia
generics
Tremeau Pharmaceuticals
hemophilic arthropathy
Flag link:
Novo taps bluebird bio for gene-editing tech
Novo taps bluebird bio for gene-editing tech
Fierce Biotech
Novo Nordisk
Bluebird Bio
R&D
gene editing
hemophilia
Flag link:
BioMarin drops lower dose of its hemophilia gene therapy as it eyes submissions by year-end
BioMarin drops lower dose of its hemophilia gene therapy as it eyes submissions by year-end
Fierce Biotech
Biomarin
hemophilia
gene therapy
valoctocogene roxaparvovec
valrox
hemophilia A
Flag link:
Pages
1
2
3
4
5
6
next ›
last »